MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

From Medicineworld.org: Phase III Clinical Trial on Pleural Mesothelioma

Mesothelioma main Diagnosis of mesothelioma Symptoms of mesothelioma  


Do You Read All Of Our Cancer Blogs?

Do You Read All Of Blogs?
Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.

Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.

Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.

Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.

Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.

Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.

Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.

Janet      

Phase III Clinical Trial on Pleural Mesothelioma


Phase III Clinical Trial on Pleural Mesothelioma
Emory Winship Cancer Institute will be one of two facilities in Georgia to conduct a phase III clinical trial of Vorinostat (oral suberoylanilide hydromaxic acid) in patients with advanced cancerous pleural mesothelioma. The purpose of the study is to test the safety and efficacy of Vorinostat as well as to compare the overall survival associated with therapy of the drug.

A rare but devastating disease, it is estimated that 2,000 to 3,000 new mesothelioma cases will be diagnosed each year in the United States. Mesothelioma is cancer of the cells found in the mesothelium, which is the protective lining covering most of the internal organs of the body. Pleural mesothelioma is the most common type of mesothelioma, and it is identified by the presence of malignant cells located in the tissue outside of the lungs and inside of the ribs.

Vorinostat is an experimental drug that is believed to work against cancer cells. When cells become malignant, chemical reactions inside the cancer cell allow those cells to multiply out of control. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

The principal investigator on the Vorinostat clinical trial at Winship is Dong M. Shin, MD, Professor of Hematology/Oncology and Otolaryngology; Director of Clinical and Translational Cancer Prevention Programs; and Co-Director of the Lung and Aerodigestive Tract Malignancies Program at Emory Winship Cancer Institute. Dr. Shin joined Winship in 2003 after more than 15 years as a faculty member at M.D. Anderson Cancer Center in Houston and the University of Pittsburgh Cancer Institute.

"This is a very important study for this terrible disease," said Dr. Shin. "As a second line treatment, there are currently no options other than this clinical trial."

Eligibility for the Vorinostat clinical trial requires a diagnosis of unidimensionally measurable cancerous pleural mesothelioma, which has progressed or relapsed following therapy with pemetrexed in combination with either Cisplastin or Carboplatin. For more information about this trial, contact Martha Forrester at 404-778-5849.


Source: Emory University


Did you know?
Emory Winship Cancer Institute will be one of two facilities in Georgia to conduct a phase III clinical trial of Vorinostat (oral suberoylanilide hydromaxic acid) in patients with advanced cancerous pleural mesothelioma. The purpose of the study is to test the safety and efficacy of Vorinostat as well as to compare the overall survival associated with therapy of the drug.

Medicineworld.org: Phase III Clinical Trial on Pleural Mesothelioma

Chemotherapy of malignant mesothelioma| Clinical features of mesothelioma| Determination of stage in malignant mesothelioma| Diagnosis of mesothelioma| Do family members of asbestos workers have a higher risk of mesothelioma| Epidemiology of mesothelioma| Frequently asked questions faq in mesothelioma| Gene therapy of mesothelioma| History of asbestos and mesothelioma| History of asbestos associated mesothelioma| How does asbestos cause mesothelioma| Mesothelioma| Mechanism of asbestos cancer induction| Mesothelioma with no history of asbestos exposure| Molecular basis of mesothelioma| Multimodality treatment of malignant mesothelioma| Natural history of malignant mesothelioma| Radiation therapy for malignant mesothelioma| Staging of pleural mesothelioma| Surgical control of pleural effusion| Surgical treatment of malignant mesothelioma| Who are at high risk for development of mesothelioma|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.